Tumor hypoxia

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

WikiDoc Resources for Tumor hypoxia

Articles

Most recent articles on Tumor hypoxia

Most cited articles on Tumor hypoxia

Review articles on Tumor hypoxia

Articles on Tumor hypoxia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tumor hypoxia

Images of Tumor hypoxia

Photos of Tumor hypoxia

Podcasts & MP3s on Tumor hypoxia

Videos on Tumor hypoxia

Evidence Based Medicine

Cochrane Collaboration on Tumor hypoxia

Bandolier on Tumor hypoxia

TRIP on Tumor hypoxia

Clinical Trials

Ongoing Trials on Tumor hypoxia at Clinical Trials.gov

Trial results on Tumor hypoxia

Clinical Trials on Tumor hypoxia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tumor hypoxia

NICE Guidance on Tumor hypoxia

NHS PRODIGY Guidance

FDA on Tumor hypoxia

CDC on Tumor hypoxia

Books

Books on Tumor hypoxia

News

Tumor hypoxia in the news

Be alerted to news on Tumor hypoxia

News trends on Tumor hypoxia

Commentary

Blogs on Tumor hypoxia

Definitions

Definitions of Tumor hypoxia

Patient Resources / Community

Patient resources on Tumor hypoxia

Discussion groups on Tumor hypoxia

Patient Handouts on Tumor hypoxia

Directions to Hospitals Treating Tumor hypoxia

Risk calculators and risk factors for Tumor hypoxia

Healthcare Provider Resources

Symptoms of Tumor hypoxia

Causes & Risk Factors for Tumor hypoxia

Diagnostic studies for Tumor hypoxia

Treatment of Tumor hypoxia

Continuing Medical Education (CME)

CME Programs on Tumor hypoxia

International

Tumor hypoxia en Espanol

Tumor hypoxia en Francais

Business

Tumor hypoxia in the Marketplace

Patents on Tumor hypoxia

Experimental / Informatics

List of terms related to Tumor hypoxia

Overview

Tumor hypoxia is the situation where tumor cells have been deprived of oxygen. Hypoxic tumor cells usually resist to radiotherapy and chemotherapy [1] as they can be made more susceptible to treatment by increasing the amount of oxygen in them, but bioreductive prodrugs play a significant part in dealing with this kind of cells: they can kill the oxygen-deficient tumor cells selectively as hypoxic cytotoxins. Study of tumors in such conditions was pioneered by Dr L. H. Gray.

It can also be a result of the high degree of cell proliferation undergone in tumor tissue, causing a higher cell density, and thus taxing the local oxygen supply.

See also

References

  1. W. A. Denny, Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 2001, 36, 577–595

Template:WH Template:WS